Financials

Discussions Technicals Seasonals

389030 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

GENINUS, Inc. engages in the research and development of NGS (Next Generation Sequencing)-based genome analysis technology and solutions. Its products include the following: CancerSCAN, an NGS cancer diagnosis service; LiquidSCAN, a liquid biopsy NGS test; Celinus, a single-cell genome analysis service; and HealthSCAN, a genetic testing service that tests innate genes to identify diseases that each person is vulnerable to. The company was founded on April 20, 2018 and is headquartered in Seoul, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

389030 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company